Abstract
The tripeptide glycine-proline-glutamate (GPE) is the naturally cleaved N-terminal tripeptide of insulin-like growth factor-1 (IGF-1) in brain tissues by an acid protease. Although GPE does not bind to IGF-1 receptors and its mode of action is not clear, in vitro studies have demonstrated its ability to stimulate acetylcholine and dopamine release, as well as to protect neurones from diverse induced brain injures. More importantly, GPE has been shown to have potent neuroprotective effects in numerous animal models of hypoxic-ischemic brain injury and neurodegenerative diseases such as Parkinsons, Alzheimers and Huntingtons diseases. As a consequence, GPE was suggested to be a potential target for the rational design of neuroprotective agents. Unfortunately, the use of GPE as a therapeutic agent is limited because of its unfavorable biochemical and pharmacokinetic properties. This review will focus on structural modifications performed on the GPE molecule in order to obtain bioactive analogues with increased pharmacokinetic profile useful for the treatment of central nervous system (CNS) injures and neurodegenerative disorders.
Keywords: Glycine-proline-glutamate, GPE analogues, macrocyclic GPE analogues, structure-activity relationships, neuroprotective agents, neurodegenerative disease, hypoxic-ischemic brain injury, Huntington's diseases, neurodegenerative diseases, Ligand-receptor interactions, amino-terminal glycine, carboxy-teminal glutamate, postoperative period, proline-analogues
Mini-Reviews in Medicinal Chemistry
Title: GPE and GPE Analogues as Promising Neuroprotective Agents
Volume: 12 Issue: 1
Author(s): I. Cacciatore, C. Cornacchia, L. Baldassarre, E. Fornasari, A. Mollica, A. Stefanucci and F. Pinnen
Affiliation:
Keywords: Glycine-proline-glutamate, GPE analogues, macrocyclic GPE analogues, structure-activity relationships, neuroprotective agents, neurodegenerative disease, hypoxic-ischemic brain injury, Huntington's diseases, neurodegenerative diseases, Ligand-receptor interactions, amino-terminal glycine, carboxy-teminal glutamate, postoperative period, proline-analogues
Abstract: The tripeptide glycine-proline-glutamate (GPE) is the naturally cleaved N-terminal tripeptide of insulin-like growth factor-1 (IGF-1) in brain tissues by an acid protease. Although GPE does not bind to IGF-1 receptors and its mode of action is not clear, in vitro studies have demonstrated its ability to stimulate acetylcholine and dopamine release, as well as to protect neurones from diverse induced brain injures. More importantly, GPE has been shown to have potent neuroprotective effects in numerous animal models of hypoxic-ischemic brain injury and neurodegenerative diseases such as Parkinsons, Alzheimers and Huntingtons diseases. As a consequence, GPE was suggested to be a potential target for the rational design of neuroprotective agents. Unfortunately, the use of GPE as a therapeutic agent is limited because of its unfavorable biochemical and pharmacokinetic properties. This review will focus on structural modifications performed on the GPE molecule in order to obtain bioactive analogues with increased pharmacokinetic profile useful for the treatment of central nervous system (CNS) injures and neurodegenerative disorders.
Export Options
About this article
Cite this article as:
Cacciatore I., Cornacchia C., Baldassarre L., Fornasari E., Mollica A., Stefanucci A. and Pinnen F., GPE and GPE Analogues as Promising Neuroprotective Agents, Mini-Reviews in Medicinal Chemistry 2012; 12 (1) . https://dx.doi.org/10.2174/138955712798868995
DOI https://dx.doi.org/10.2174/138955712798868995 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Schizophrenia and the Neglect Syndrome: Parietal Contributions to Cognitive Dysfunction in Schizophrenia
Current Psychiatry Reviews Preface [Hot Topic: New Clinical Applications for Naturally Occurring Peptide Toxins (Guest Editors: Robert Jones / Graeme Semple)]
Current Medicinal Chemistry Psychological Problems in Female Fragile X Premutations Carriers
Current Psychiatry Reviews Endocannabinoids in Neuroimmunology and Stress
Current Drug Targets - CNS & Neurological Disorders Current Aspects of Pathophysiology and Cell Dysfunction after Severe Head Injury
Current Pharmaceutical Design Tactile Angle Discrimination Decreases due to Subjective Cognitive Decline in Alzheimer’s Disease
Current Alzheimer Research Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Defining and Regulating Acute Inflammatory Lesion Formation during the Pathogenesis of Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
CNS & Neurological Disorders - Drug Targets Role of Deoxyribonucleoside Kinases and Deoxyribonucleotide Pool Alterations in Nucleoside Reverse Transcriptase Inhibitor Induced Mitochondrial Toxicity
Current Medicinal Chemistry - Anti-Infective Agents Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry The Chemistry and Pharmacology of Tetrahydropyridines
Current Medicinal Chemistry Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design Sex Steroid Hormone Effects in Normal and Pathologic Conditions in Lung Physiology
Mini-Reviews in Medicinal Chemistry A Review on Response of Immune System in Spinal Cord Injury and Therapeutic Agents useful in Treatment
Current Pharmaceutical Biotechnology The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Organotypic Cultures as Tool to Test Long-Term Effects of Chemicals on the Nervous System
Current Medicinal Chemistry Management and Treatment of Cardiovascular Diseases in the Elderly
Current Pharmacogenomics and Personalized Medicine Novel Insights for Multiple Sclerosis and Demyelinating Disorders with Apoptosis, Autophagy, FoxO, and mTOR
Current Neurovascular Research Control of Stemness by Fibroblast Growth Factor Signaling in Stem Cells and Cancer Stem Cells
Current Stem Cell Research & Therapy Therapeutic Approaches of Leptin in Alzheimers Disease
Recent Patents on CNS Drug Discovery (Discontinued)